Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.

Jonathan M Loree Emma Titmuss James T Topham Hagen F Kennecke Harriet E Feilotter Shakeel Virk Young S Lee Kimberly C Banks Katie Quinn Aly Karsan Daniel J Renouf Derek J Jonker Dongsheng Tu Chris J O'Callaghan Eric X Chen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

pTMB derived from either clonal or subclonal mutations may identify a group more likely to benefit from immunotherapy, though validation is required. Tissue TMB provided no predictive utility for immunotherapy in this trial.

Keyphrases

metastatic colorectal cancer
phase iii
study protocol
phase ii
clinical trial
randomized controlled trial
open label
risk factors